These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26354926)

  • 1. Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases.
    Sharma PA; Maheshwari R; Tekade M; Tekade RK
    Curr Pharm Des; 2015; 21(30):4465-78. PubMed ID: 26354926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendrimers as an Effective Nanocarrier in Cardiovascular Disease.
    Gothwal A; Kesharwani P; Gupta U; Khan I; Iqbal Mohd Amin MC; Banerjee S; Iyer AK
    Curr Pharm Des; 2015; 21(30):4519-26. PubMed ID: 26311317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases.
    Rao S; Tan A; Thomas N; Prestidge CA
    J Control Release; 2014 Nov; 193():174-87. PubMed ID: 24852093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-constructed Carriers Loaded With Antioxidant: Boon For Cardiovascular System.
    Jain A; Kesharwani P; Garg NK; Jain A; Nirbhavane P; Dwivedi N; Banerjee S; Iyer AK; Iqbal Mohd Amin MC
    Curr Pharm Des; 2015; 21(30):4456-64. PubMed ID: 26234791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities.
    Jain AK; Mehra NK; Swarnakar NK
    Curr Pharm Des; 2015; 21(30):4441-55. PubMed ID: 26234792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remote magnetic targeting of iron oxide nanoparticles for cardiovascular diagnosis and therapeutic drug delivery: where are we now?
    Bietenbeck M; Florian A; Faber C; Sechtem U; Yilmaz A
    Int J Nanomedicine; 2016; 11():3191-203. PubMed ID: 27486321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nano-Medicine as a Newly Emerging Approach to Combat Human Immunodeficiency Virus (HIV).
    Saravanan M; Asmalash T; Gebrekidan A; Gebreegziabiher D; Araya T; Hilekiros H; Barabadi H; Ramanathan K
    Pharm Nanotechnol; 2018; 6(1):17-27. PubMed ID: 29424324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theranostic Applications of Nanomaterials in the Field of Cardiovascular Diseases.
    Sahoo RK; Singh H; Thakur K; Gupta U; Goyal AK
    Curr Pharm Des; 2022; 28(2):91-103. PubMed ID: 34218771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Therapeutic Strategies for Cardiovascular Disease Treatment: From Molecular Level to Nanotechnology.
    Vaidya B; Gupta V
    Curr Pharm Des; 2015; 21(30):4367-9. PubMed ID: 26377649
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ignoring the modeling approaches: Towards the shadowy paths in nanomedicine.
    Hassanzadeh P; Atyabi F; Dinarvand R
    J Control Release; 2018 Jun; 280():58-75. PubMed ID: 29723612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The physiology of cardiovascular disease and innovative liposomal platforms for therapy.
    Ruiz-Esparza GU; Flores-Arredondo JH; Segura-Ibarra V; Torre-Amione G; Ferrari M; Blanco E; Serda RE
    Int J Nanomedicine; 2013; 8():629-40. PubMed ID: 23413209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicine applied to cardiovascular diseases: latest developments.
    Martín Giménez VM; Kassuha DE; Manucha W
    Ther Adv Cardiovasc Dis; 2017 Apr; 11(4):133-142. PubMed ID: 28198204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Oxidative Stress Using Nanoparticles as a Theranostic Strategy for Cardiovascular Diseases.
    Kim KS; Song CG; Kang PM
    Antioxid Redox Signal; 2019 Feb; 30(5):733-746. PubMed ID: 29228781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug 'Etoposide'.
    Choudhury H; Maheshwari R; Pandey M; Tekade M; Gorain B; Tekade RK
    Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110275. PubMed ID: 31753398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theranostic nanoparticles for cancer and cardiovascular applications.
    Wang D; Lin B; Ai H
    Pharm Res; 2014 Jun; 31(6):1390-406. PubMed ID: 24595494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inorganic Nanoparticles for Cancer Therapy: A Transition from Lab to Clinic.
    Bayda S; Hadla M; Palazzolo S; Riello P; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4269-4303. PubMed ID: 29284391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring.
    Namiki Y; Fuchigami T; Tada N; Kawamura R; Matsunuma S; Kitamoto Y; Nakagawa M
    Acc Chem Res; 2011 Oct; 44(10):1080-93. PubMed ID: 21786832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendrimer-nanoparticle conjugates in nanomedicine.
    Parat A; Bordeianu C; Dib H; Garofalo A; Walter A; Bégin-Colin S; Felder-Flesch D
    Nanomedicine (Lond); 2015; 10(6):977-92. PubMed ID: 25867861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.